Quarterly Earnings

Malaysian solar firm FGL faces delisting after a reverse stock split, meant to save its listing, backfired and wiped out its public share float.

Industry veteran Patrick Söderlund takes the helm as Nexon's Executive Chairman, signaling a major strategic pivot toward Western markets and creative renewal.

As MARA preps its Q4 earnings call, investors look beyond Bitcoin to see if its ambitious digital energy and AI infrastructure strategy is paying off.

F&G Annuities & Life declared its quarterly dividend, offering a sign of stability even as a recent earnings report and stock drop raise questions.

After selling its wireless unit, TDS reports soaring profits and announces aggressive new growth targets for its fiber broadband and tower businesses.

As Sectra prepares its nine-month report, all eyes are on its performance as a key indicator for the converging medical IT and cybersecurity sectors.

Weave posts strong 2025 results, leveraging AI and key partnerships with CareCredit and the ADA to redefine the healthcare practice front office.

Investors eye BBVA Argentina's upcoming FY2025 report for insights into its resilience and growth against a backdrop of high inflation and policy changes.

Kurv's new KCOP ETF offers investors a unique way to play the copper market, combining mining exposure with an options strategy for enhanced income.

eHealth is ditching its transactional model for lifelong support, but can it win over skeptical consumers and investors in a competitive market?

Pharma giant AbbVie raises its dividend, backed by robust financials and a powerful drug pipeline that signals a thriving post-Humira growth era.

For the tenth straight year, Sprout Social has won G2's Best Software award. See how its AI pivot and deep customer loyalty are redefining social intelligence.

Cloud security leader Zscaler prepares for high-stakes investor conferences, aiming to showcase its financial strength and AI-driven growth strategy.

Clene Inc. faces investors with promising data for ALS and MS, but a looming cash crunch makes its upcoming conference a critical test of survival.

Innoviva prepares for a key investor conference, spotlighting its shift to specialty drugs and navigating questions on its diversified growth strategy.

Reunion Neuroscience hits the investor conference circuit, seeking capital to advance its groundbreaking psychedelic-inspired therapies for depression and anxiety.

The PXM leader surpassed the coveted 'Rule of 40' financial benchmark in 2025, signaling strong growth and profitability as it preps for an AI-driven future.

Benefits giant Alight faces a massive $3.1B annual loss from a goodwill writedown, suspending its dividend to focus on debt reduction and AI innovation.

With two blockbuster cancer drugs driving record revenue, all eyes are on Syndax's upcoming earnings call for its 2026 outlook and growth strategy.

As Signet prepares its Q4 earnings, all eyes are on whether its brand power can overcome cautious consumer spending and set the tone for the luxury market.